Cargando…
From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
Treatment of Myasthenia Gravis (MG) is still based on non-specific immunosuppression. Long-term high dose corticosteroids is still a major cause of side effects, in young as well as in elderly patients in whom comorbidities further increase the burden of chronic immunosuppression. Moreover, awarenes...
Autores principales: | Mantegazza, Renato, Antozzi, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492201/ https://www.ncbi.nlm.nih.gov/pubmed/32982957 http://dx.doi.org/10.3389/fneur.2020.00981 |
Ejemplares similares
-
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018) -
Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023) -
Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011) -
User Involvement in Myasthenia Gravis Research
por: Gilhus, Nils Erik, et al.
Publicado: (2022) -
Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)